MC7 THE PHARMACOGENOMICS BIAS IN DECISION MODELS

Pharmacogenomics Bias - Systematic distortion of study results by genetic heterogeneity

BACKGROUND Decision analyses of drug treatments in chronic diseases require modeling the progression of disease and treatment response beyond the time horizon of clinical or epidemiological studies. In many such models, progression and drug effect have been applied uniformly to all patients; heterogeneity in progression, including pharmacogenomic effects, has been ignored. OBJECTIVE We sought...

Pharmacogenomics approach in psychiatry disorders

Psychiatric disorders are important health issues in the world, and their management is facing some serious challenges. Drugs that are widely used in the treatment of psychiatric disorders, including antidepressants, antipsychotics, and mood stabilizers, are often associated with many side effects and are adequately effective only in a small proportion of patients. Many factors, including genet...

The reality of pharmacogenomics: optimizing therapeutic decision making.

is now well established that significant interindividual variability exists in the disposition and pharmacologic effects of certain medications. Influences such as environmental exposures, nutritional status, co-morbidities, severity of disease, and concomitant medications have all been associated with heterogeneity in drug responses. In addition, the profound contribution of genetics has been ...

Outcome bias in decision evaluation.

In 5 studies, undergraduate subjects were given descriptions and outcomes of decisions made by others under conditions of uncertainty. Decisions concerned either medical matters or monetary gambles. Subjects rated the quality of thinking of the decisions, the competence of the decision maker, or their willingness to let the decision maker decide on their behalf. Subjects understood that they ha...

A hybrid decision making system using DEA and fuzzy models for supplier selection in the presence of multiple decision makers